ELANCO ANIMAL HEALTH INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.04 USD | -2.03% |
|
-3.91% | -12.48% |
| Apr. 01 | Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board | MT |
| Apr. 01 | Elanco appoints two directors after settling with activist Ancora | RE |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.67% | 6.56B | B- | ||
| +16.00% | 3.43B | B- | ||
| -1.11% | 3.22B | B- | ||
| +0.34% | 1.46B | - | ||
| -14.67% | 1.38B | B | ||
| -3.12% | 1.26B | - | ||
| -27.57% | 1.21B | C- | ||
| -12.86% | 1.14B | - | ||
| -2.99% | 1.02B | - | ||
| -8.55% | 835M | D+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ELAN Stock
- Ratings Elanco Animal Health Incorporated
